Glucose Competence of the Hepatoportal Vein Sensor Requires the Presence of an Activated Glucagon-Like Peptide-1 Receptor
- 1 August 2001
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 50 (8) , 1720-1728
- https://doi.org/10.2337/diabetes.50.8.1720
Abstract
Activation of the hepatoportal glucose sensors by portal glucose infusion leads to increased glucose clearance and induction of hypoglycemia. Here, we investigated whether glucagon-like peptide-1 (GLP-1) could modulate the activity of these sensors. Mice were therefore infused with saline (S-mice) or glucose (P-mice) through the portal vein at a rate of 25 mg/kg · min. In P-mice, glucose clearance increased to 67.5 ± 3.7 mg/kg · min as compared with 24.1 ± 1.5 mg/kg · min in S-mice, and glycemia decreased from 5.0 ± 0.1 to 3.3 ± 0.1 mmol/l at the end of the 3-h infusion period. Coinfusion of GLP-1 with glucose into the portal vein at a rate of 5 pmol/kg · min (P–GLP-1 mice) did not increase the glucose clearance rate (57.4 ± 5.0 ml/kg · min) and hypoglycemia (3.8 ± 0.1 mmol/l) observed in P-mice. In contrast, coinfusion of glucose and the GLP-1 receptor antagonist exendin-(9-39) into the portal vein at a rate of 0.5 pmol/kg · min (P-Ex mice) reduced glucose clearance to 36.1 ± 2.6 ml/kg · min and transiently increased glycemia to 9.2 ± 0.3 mmol/l at 60 min of infusion before it returned to the fasting level (5.6 ± 0.3 mmol/l) at 3 h. When glucose and exendin-(9-39) were infused through the portal and femoral veins, respectively, glucose clearance increased to 70.0 ± 4.6 ml/kg · min and glycemia decreased to 3.1 ± 0.1 mmol/l, indicating that exendin-(9-39) has an effect only when infused into the portal vein. Finally, portal vein infusion of glucose in GLP-1 receptor−/− mice failed to increase the glucose clearance rate (26.7 ± 2.9 ml/kg · min). Glycemia increased to 8.5 ± 0.5 mmol/l at 60 min and remained elevated until the end of the glucose infusion (8.2 ± 0.4 mmol/l). Together, our data show that the GLP-1 receptor is part of the hepatoportal glucose sensor and that basal fasting levels of GLP-1 sufficiently activate the receptor to confer maximum glucose competence to the sensor. These data demonstrate an important extrapancreatic effect of GLP-1 in the control of glucose homeostasis.Keywords
This publication has 33 references indexed in Scilit:
- The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-l, but not to glucose-dependent insulinotropic polypeptide, in the portal veinPublished by Elsevier ,1999
- Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine IntestineEndocrinology, 1999
- Exendin-(9-39) Is an Inverse Agonist of the Murine Glucagon-Like Peptide-1 Receptor: Implications for Basal Intracellular Cyclic Adenosine 3',5'-Monophosphate Levels and -Cell Glucose CompetenceEndocrinology, 1998
- ENTEROGLUCAGONAnnual Review of Physiology, 1997
- Novel glucosensor for hypoglycemic detection localized to the portal veinDiabetes, 1997
- Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigmDiabetes, 1996
- Glucagon-like peptide-I and the control of insulin secretion in the normal state and in NIDDMDiabetes, 1993
- Gut hormones and diabetes mellitusDiabetes/Metabolism Research and Reviews, 1992
- A portal‐arterial glucose concentration gradient as a signal for an insulin‐dependent net glucose uptake in perfused rat liverFEBS Letters, 1986
- Evidence for a role of the gastric, coeliac and hepatic branches in vagally stimulated insulin secretion in the ratJournal of the Autonomic Nervous System, 1983